
|Articles|June 18, 2007
Latebreakers: Revision made of Actos label
A request from the FDA has led to a revision of the prescribing information for pioglitazone (Actos, Takeda Pharmaceuticals).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
CDC Will Focus on BA.2.3 COVID-19 Variant for Upcoming Respiratory Season
2
Alabama Board of Medical Examiners Issues Warning of Non-FDA-Approved Peptides
3
Executive Order Calls for Realignment of Childhood Vaccines
4
HHS Using AI Initiative to Uncover Health Care Fraud, Waste
5




















































